# US 2021/0330732 A1 · Method of making solanaceae fruit extracts > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2021/0330732 A1 - Document ID: US20210330732A1 - Status: Published application - Kind: A1 - Application number: 17/192,155 - Filed: 2021-03-04 - Published: 2021-10-28 - Earliest claimed: 2008-10-31 - Assignees: Provexis Natural Products Limited - Applicants: Provexis Natural Products Limited - Inventors: Niamh O'Kennedy - Web page: https://patentgrep.com/patent/US20210330732A1 ## CPC - A61K 36/81: Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed - A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} - A61K 31/7064: containing condensed or non-condensed pyrimidines - A61P 7/00: Drugs for disorders of the blood or the extracellular fluid - A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Provided are methods of making an extract of fruit of the Solanaceae family wherein fruit is processed to optimise the platelet aggregation inhibiting activity of the extract. The methods involve preparing a start mix of homogenised fruit; separating a water soluble fraction from fruit solids; filtration of the water soluble fraction; and concentration of active agents in the filtration permeate. The invention also provides fruit extracts manufactured by such methods, and also fruit extracts containing glycosylated phenolic acid or a phenolic ester, or derivatives thereof; a glycosylated flavonoid; and a nucleoside. The extracts of the invention are useful as medicaments for the treatment or prevention of a medical condition characterised by inappropriate platelet aggregation. In particular, the medicaments may be of use in maintaining heart health by reducing platelet aggregation; benefiting the circulation; and/or normalizing or otherwise benefiting blood flow. ## Claims ### Claim at position 1 1-23. (canceled) ### Claim 24 A substantially lycopene-free extract of fruit of the Solanaceae family comprising: (a) glycosylated phenolic acid or a phenolic ester, or derivatives thereof; (b) a glycosylated flavonoid; and (c) a nucleoside; wherein the extract contains <1% sugars and contains >95% of the bioactive components (a), (b) and (c) that are contained in a start mix from which the extract is prepared. ### Claim 25 (depends on 24) The substantially lycopene-free extract of claim 24, further comprising an excipient. ### Claim 26 (depends on 24) The substantially lycopene-free extract of claim 24 wherein the glycosylated phenolic acid or a phenolic ester is a glycosylated cinnamic acid or derivative thereof and may be selected from the group comprising Caffeoyl-4-O-quinic acid, Caffeoyl-4-O-glucoside, Coumaroyl-4-O-glycoside (gluc/gal) and Coumaroyl-4-O-glycoside (disaccharide). ### Claim 27 (depends on 24) The substantially lycopene-free extract of claim 24 wherein the glycosylated phenolic acid or a phenolic ester is selected from: Caffeic acid glucoside; p-Coumaric acid hexose/dihydrokaempferol hexose; Ferulic acid glycoside; and a p-Coumaric acid derivative. ### Claim 28 (depends on 24) The substantially lycopene-free extract of claim 24 wherein the glycosylated flavonoid is Quercetin-3-O-glucoside or Rutin. ### Claim 29 (depends on 24) The substantially lycopene-free extract of claim 24 wherein the nucleoside is selected from the group comprising AMP, Uridine, Adenosine, Guanosine or GMP. ### Claim 30 (depends on 24) The substantially lycopene-free extract of claim 24 formulated as a solution, suspension, syrup, tablet, capsule or lozenge. ### Claim 31 (depends on 24) A dosage form of the substantially lycopene-free extract of claim 24 comprising 10 -500 mg dry weight of the extract. ### Claim 32 (depends on 31) The dosage form of claim 31, further comprising an excipient. ### Claim 33 (depends on 31) The dosage form of claim 31, comprising between about 85 mgs and about 150 mg dry weight of the extract. ### Claim 34 A method for treating or inhibiting a medical condition characterised by inappropriate platelet aggregation comprising administering a substantially lycopene-free extract of tomato fruit to a subject in need thereof, wherein the substantially lycopene-free extract comprises: (a) glycosylated phenolic acid or a phenolic ester, or derivatives thereof; (b) a glycosylated flavonoid; and (c) a nucleoside; and wherein the substantially lycopene-free extract contains <1% sugars and contains >95% of the bioactive components (a), (b) and (c) that are contained in a tomato fruit start mix from which the extract is prepared. ### Claim 35 (depends on 34) The method of claim 34, wherein the treatment or inhibition of the medical condition characterised by inappropriate platelet aggregation is for a purpose selected from the group consisting of: maintaining heart health by reducing platelet aggregation; benefiting the circulation; and normalizing or otherwise benefiting blood flow. ### Claim 36 (depends on 35) The method of claim 35, wherein the substantially lycopene-free extract: (a) reduces occurrence of a hypercoagulable or prothrombotic state; (b) reduce development of atherosclerosis; (c) reduces development of coronary disease; (d) reduces development of restenosis following angioplasty and bypass procedures; (e) treats coronary disease resulting from thrombo-embolic disorders; reduces the risk of deep vein thrombosis; (g) benefits the circulation to maintain good circulatory health; or (h) maintains healthy blood flow in the cardiovascular system. ### Claim 37 An substantially lycopene free extract of fruit of the Solanaceae family having optimized platelet aggregation inhibiting activity made by a process, comprising: (a) preparing a start mix of homogenized fruit, wherein the start mix has a pH that does not exceed 5.5 and the start mix is held at a temperature that does not exceed 35° C.; (b) separating a water soluble fraction from the start mix from insoluble solids of the start mix, wherein the water soluble fraction is obtained without raising the temperature of the fraction above 60° C.; (c) filtering the water soluble fraction; (d) removing free sugars from the filtered water soluble fraction with a food grade resin, wherein the resin adsorbs components from the fraction but does not adsorb free sugars, organic acids and salts, wherein the adsorbed components are recovered from the resin by elution with an ethanol/water mixture to provide a solution, and wherein ethanol is removed from the solution by evaporation under reduced pressure or by reverse osmosis; and (e) concentrating the solution to provide the extract of fruit of the Solanaceae family, wherein the extract is a concentrated aqueous solution containing <1% sugar and >95% of bioactive components contained in the start mix. ### Claim 38 (depends on 37) The substantially lycopene free extract of claim 37, wherein the browning index of the start mix does not exceed 0.4 AU at 4% solids. ### Claim 39 (depends on 37) The substantially lycopene free extract of claim 37, wherein the sugars are removed by resin-mediated separation. ### Claim 40 (depends on 37) The substantially lycopene free extract of claim 37, wherein the extract is further processed into a powder. ### Claim 41 (depends on 37) The substantially lycopene free extract of claim 37, wherein the start mix is diluted and comprises less than 33% solids. ### Claim 42 (depends on 37) The substantially lycopene free extract of claim 37, further comprising an excipient.